Tânia Moura

Mrs. Tânia Moura

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
Tânia MouraTânia Moura
Tânia Moura
Paula LaranjeiraPaula Laranjeira
Paula Laranjeira
OCOlga Caramelo
Olga Caramelo
Ana GilAna Gil
Ana Gil
APArtur Paiva
Artur Paiva
Breast cancer is the most common type of cancer in women and the second leading cause of death by cancer. Despite recent advances, the mortality rate remains high, underlining the need to develop new therapeutic approaches. The complex interaction between cancer cells and the tumor microenvironment (TME) is crucial in determining tumor progression, therapy response, and patient prognosis. Understanding the role of immune cells in carcinogenesis and tumor progression can help improve targeted therapeutic options, increasing the likelihood of a favorable prognosis. Therefore, this review aims to critically analyze the complex interaction between tumor cells and immune cells, emphasizing the clinical and therapeutic implications. Additionally, we explore advances in immunotherapies, with a focus on immune checkpoint inhibitors.

7 January 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
Tânia MouraTânia Moura
Tânia Moura
OCOlga Caramelo
Olga Caramelo
ISIsabel Silva
Isabel Silva
SSSandra Silva
Sandra Silva
MGManuela Gonçalo
Manuela Gonçalo
APArtur Paiva
Artur Paiva
Background: Breast cancer is a heterogeneous malignant disease with a varying prognosis and is classified into four molecular subtypes. It remains one of the most prevalent cancers globally, with the tumor microenvironment playing a critical role in disease progression and patient outcomes. Methods: This study evaluated tumor samples from 40 female patients with luminal A and B breast cancer, utilizing flow cytometry to phenotypically characterize the immune cells and tumor cells present within the tumor tissue. Results: The luminal B-like tumor samples exhibited increased infiltration of CD4+ cells, regulatory T cells (Tregs), and Th17 cells and decreased levels of NK cells, γδ T cells, Th1 cells, and follicular T cells, which is indicative of a more immunosuppressive tumor microenvironment. Conclusions: These findings suggest that luminal B-like tumors have a microenvironment that is less supportive of effective anti-tumor immune responses compared to luminal A tumors. This study enhances the understanding of the immunological differences between luminal subtypes of breast cancer and identifies potential new therapeutic targets and biomarkers that could drive advancements in precision medicine for breast cancer management.

27 June 2023 in Veterinarska stanica
Verified
Journal Article
Open access
PDF file
TATiago Azevedo
Tiago Azevedo
JSJessica Silva
Jessica Silva
FPFrancisco Peixoto
Francisco Peixoto
ASAna C. Silvestre-Ferreira
Ana C. Silvestre-Ferreira
AGAdelina Gama
Adelina Gama
MNMaria J. Neuparth
Maria J. Neuparth
Breast cancer is the most diagnosed cancer among women, and a leading cause of death worldwide. Santolina chamaecyparissus L. is a plant with multiple health benefits, including anticancer and anti-diabetic properties. This study aimed to assess the...

14 November 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Tânia MouraTânia Moura
Tânia Moura
OCOlga Caramelo
Olga Caramelo
ISIsabel Silva
Isabel Silva
SSSandra Silva
Sandra Silva
Paula LaranjeiraPaula Laranjeira
Paula Laranjeira
APArtur Paiva
Artur Paiva
Background: Luminal A breast cancer, the most common molecular subtype, is typically associated with a favorable prognosis. However, its systemic immune landscape remains largely uncharacterized. Methods: In this study, we used high-dimensional flow cytometry to characterize peripheral immune alterations in 13 patients with luminal A breast cancer compared to 14 age-matched healthy female controls. A total of 254 immune subsets were analyzed, including 23 innate populations and 231 T cell subpopulations, defined by detailed phenotypic and functional markers. Results: The main observations in the luminal A breast cancer group included a significant increase in neutrophils, plasmacytoid dendritic cells (pDCs), and CD4+ follicular T lymphocytes, as well as a reduced percentage of monocytes, conventional type 2 dendritic cells (cDC2), and CD4+CD196+ T cells. Conclusions: Despite being a preliminary study, these findings highlight distinct immune alterations in luminal A breast cancer and support the use of flow cytometry for identifying biomarkers, measurable biological indicators of disease presence, progression, or therapeutic response.